Sign in
CompletedPhase 2

Effect of Telitacicept on Antibody Titers in Primary APS Patients

Key facts

Who runs it
Ruijin Hospital
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 2
People taking part
20 people enrolled
Started
1 Dec 2023
Ended
6 Jan 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Telitacicept+SOC
  • SOC
Record updated
20 January 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • Age ≥18 years
  • Diagnosis of primary APS, meet 2006 Sydney classification criteria or continuously positive for antiphospholipid antibodies within the first 12 months of inclusion (tested at least every 12 weeks), classified as high-risk antiphospholipid antibody spectrum based on the risk of antibody levels, in order to meet at least one of the following conditions: 1. Positive lupus anticoagulant (LAC) (tested according to ISTH guidelines); 2. Two or three types of aPL positivity (lupus anticoagulant, anticardiolipin antibody, and anti-β2 any two or all three types of glycoprotein I antibodies; 3. Or persistent high titer aPL
  • There are no other autoimmune diseases occurring simultaneously
  • According to EULAR recommendations for antiphospholipid syndrome, a stable APS treatment regimen should be adopted
  • Female patients who are not pregnant, breastfeeding, have no fertility potential, or have not undergone contraception

Who cannot take part

  • Patients with a current history of drug or alcohol abuse or dependence, or have a history of drug or alcohol abuse or dependence within 365 days before day 0
  • Patients with concurrent major medical or mental illnesss
  • Patients who have been vaccinated with live vaccine in the last month
  • Patients who have participated in any clinical trial within 28 days before the initial screening and/or within 5 times of the half-life of the study compound (whichever is longer)
  • Patients who use B-cell targeted therapy drugs within one year, such as rituximab or epratuzumab
  • Patients who use tumor necrosis factor inhibitor and interleukin receptor blocker within one year
  • Patients with a history of malignant tumor in the past 5 years, except for basal cell carcinoma or squamous cell carcinoma of skin or cervical carcinoma in situ treated locally, and there is no evidence of metastasis within 3 years
  • Patients with a history of primary immunodeficiency
  • Patients with a current history of infection
  • HIV test is historically positive or HIV screening is positive
  • Hepatitis status
  • Patients with a history of allergic reaction caused by injection of contrast agent, human or mouse protein or monoclonal antibody
  • Patients with diseases of liver, kidney, heart and other important organs,blood and Endocrine system
  • Patients with active infection (such as herpes zoster, HIV infection, active tuberculosis, etc.) during the screening period
  • Other conditions that the investigator considers would make the candidate unsuitable for the study
  • Serious lack of IgG (IgG level \< 400 mg/dL)
  • IgA deficiency (IgA level \< 10 mg/dL)
  • Patients with other abnormal laboratory values with clinical significance
  • If women with reproductive potential (WCBP) are included, please refer to the following special instructions
  • Patients who use Intravenous gamma globulin (IVIG) and prednisone ≥100mg/d for more than 14 days within one year or plasma exchange
  • Patients with depression or suicidal thoughts

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to evaluate the regulatory effect of Telitacicept on antibody titers in primary antiphospholipid syndrome patients carrying high-risk antiphospholipid antibody profiles.

The 2 groups in the trial

  • Experimental: SOC+Telitacicept armTreatment being tested

    Telitacicept 160mg once a week for 48 week as an add-on treatment regimen. SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.

    Treatment: Telitacicept+SOC and SOC

  • Experimental: SOC armExisting treatment, for comparison

    SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.

    Treatment: SOC

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Single Center, Randomized Controlled, Open Label Trial Exploring the Regulatory Effect of Telitacicept on Antibody Titers in Primary Antiphospholipid Syndrome Patients Carrying High-risk Antiphospholipid Antibody Profiles
Record updated
20 January 2026